These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 28434297)

  • 1. Efficiency of siRNA for removal of transthyretin V30M in a TTR leptomeningeal animal model.
    Gonçalves P; Martins H; Costelha S; Saraiva MJ
    Amyloid; 2017 Mar; 24(sup1):38-39. PubMed ID: 28434297
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficiency of silencing RNA for removal of transthyretin V30M in a TTR leptomeningeal animal model.
    Gonçalves P; Martins H; Costelha S; Maia LF; Saraiva MJ
    Amyloid; 2016 Dec; 23(4):249-253. PubMed ID: 27884058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatic production of transthyretin L12P leads to intracellular lysosomal aggregates in a new somatic transgenic mouse model.
    Batista AR; Sena-Esteves M; Saraiva MJ
    Biochim Biophys Acta; 2013 Aug; 1832(8):1183-93. PubMed ID: 23579071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suppression of choroid plexus transthyretin levels by antisense oligonucleotide treatment.
    Benson MD; Smith RA; Hung G; Kluve-Beckerman B; Showalter AD; Sloop KW; Monia BP
    Amyloid; 2010 Jun; 17(2):43-9. PubMed ID: 20462362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical evaluation of RNAi as a treatment for transthyretin-mediated amyloidosis.
    Butler JS; Chan A; Costelha S; Fishman S; Willoughby JL; Borland TD; Milstein S; Foster DJ; Gonçalves P; Chen Q; Qin J; Bettencourt BR; Sah DW; Alvarez R; Rajeev KG; Manoharan M; Fitzgerald K; Meyers RE; Nochur SV; Saraiva MJ; Zimmermann TS
    Amyloid; 2016 Jun; 23(2):109-18. PubMed ID: 27033334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modeling familial amyloidotic polyneuropathy (Transthyretin V30M) in Drosophila melanogaster.
    Berg I; Thor S; Hammarström P
    Neurodegener Dis; 2009; 6(3):127-38. PubMed ID: 19372706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impairment of autophagy by TTR V30M aggregates: in vivo reversal by TUDCA and curcumin.
    Teixeira CA; Almeida Mdo R; Saraiva MJ
    Clin Sci (Lond); 2016 Sep; 130(18):1665-75. PubMed ID: 27382986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective silencing of a mutant transthyretin allele by small interfering RNAs.
    Kurosawa T; Igarashi S; Nishizawa M; Onodera O
    Biochem Biophys Res Commun; 2005 Nov; 337(3):1012-8. PubMed ID: 16225852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transthyretin amyloidosis: a phenocopy of hypertrophic cardiomyopathy.
    Vermeer AMC; Janssen A; Boorsma PC; Mannens MMAM; Wilde AAM; Christiaans I
    Amyloid; 2017 Jun; 24(2):87-91. PubMed ID: 28475415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of albumin on transthyretin and amyloidogenic transthyretin Val30Met disposition and tissue deposition in familial amyloidotic polyneuropathy.
    Taguchi K; Jono H; Kugimiya-Taguchi T; Nagao S; Su Y; Yamasaki K; Mizuguchi M; Maruyama T; Ando Y; Otagiri M
    Life Sci; 2013 Dec; 93(25-26):1017-22. PubMed ID: 24211615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Familial amyloidotic polyneuropathy and transthyretin.
    Nagasaka T
    Subcell Biochem; 2012; 65():565-607. PubMed ID: 23225017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CNS involvement in V30M transthyretin amyloidosis: clinical, neuropathological and biochemical findings.
    Maia LF; Magalhães R; Freitas J; Taipa R; Pires MM; Osório H; Dias D; Pessegueiro H; Correia M; Coelho T
    J Neurol Neurosurg Psychiatry; 2015 Feb; 86(2):159-67. PubMed ID: 25091367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of liver transplantation and tafamidis in hereditary transthyretin amyloidosis caused by transthyretin Leu55Pro mutation: a case report.
    Kon T; Misumi Y; Nishijima H; Honda M; Suzuki C; Baba M; Inomata Y; Obayashi K; Ando Y; Tomiyama M
    Amyloid; 2015; 22(3):203-4. PubMed ID: 26123280
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical picture and outcome of transthyretin-related familial amyloid polyneuropathy (FAP) in Japanese patients.
    Ikeda S
    Clin Chem Lab Med; 2002 Dec; 40(12):1257-61. PubMed ID: 12553427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic pitfalls in sporadic transthyretin familial amyloid polyneuropathy (TTR-FAP).
    Ikeda K; Kano O; Ito H; Kawase Y; Iwamoto K; Sato R; Sekine T; Nagata R; Nakamura Y; Hirayama T; Iwasaki Y
    Neurology; 2008 Apr; 70(17):1576; author reply 1576-7. PubMed ID: 18427077
    [No Abstract]   [Full Text] [Related]  

  • 16. Patisiran for the treatment of hereditary transthyretin-mediated amyloidosis.
    Yang J
    Expert Rev Clin Pharmacol; 2019 Feb; 12(2):95-99. PubMed ID: 30644768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene therapy approach to FAP: in vivo influence of T119M in TTR deposition in a transgenic V30M mouse model.
    Batista AR; Gianni D; Ventosa M; Coelho AV; Almeida MR; Sena-Esteves M; Saraiva MJ
    Gene Ther; 2014 Dec; 21(12):1041-50. PubMed ID: 25273354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Doxycycline-tauroursodeoxycholic acid treatment: effects in the heart of a transthyretin V30M transgenic mouse model.
    Teixeira C; Costelha S; Martins HS; Teixeira A; Saraiva MJ
    Amyloid; 2017 Mar; 24(sup1):80. PubMed ID: 28434372
    [No Abstract]   [Full Text] [Related]  

  • 19. [Transthyretin-related amyloidotic cardiomyopathy: looking for the etiological treatment].
    Longhi S; Gagliardi C; Milandri A; Manuzzi L; Rapezzi C
    G Ital Cardiol (Rome); 2014 May; 15(5):293-300. PubMed ID: 25002169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Doxycycline disrupts transthyretin amyloid: evidence from studies in a FAP transgenic mice model.
    Cardoso I; Saraiva MJ
    FASEB J; 2006 Feb; 20(2):234-9. PubMed ID: 16449795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.